Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy
Status:
Terminated
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
IgA nephropathy (IgAN) is the most common type of glomerulonephritis worldwide. 15-40% of
individuals diagnosed with IgAN, including children, will eventually progress to chronic
renal insufficiency (CRI) and end stage renal disease (ESRD). The study is to evaluate the
safety and benefits of MMF in patients with IgAN who have been pre-treated (and continue to
be treated) with angiotensin converting enzyme inhibitors (ACEi) and fish oil supplements
(FOS).